Progress and prospect of inhaled biological agents in asthma
10.12092/j.issn.1009-2501.2024.04.007
- VernacularTitle:吸入性生物制剂在哮喘疾病中的开发进展及前景
- Author:
Guanghui LI
1
;
Jing HUANG
;
Min ZHU
;
Rui ZHAO
;
Yakun WAN
;
Zhihong CHEN
Author Information
1. 上海洛启生物医药技术有限公司,上海 201203
- Keywords:
asthma;
route of administration;
ad-ministration by inhalation;
biologics
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2024;29(4):406-414
- CountryChina
- Language:Chinese
-
Abstract:
More than 300 million people world-wide suffer from asthma,and the incidence is in-creasing year by year.As one of the most common chronic diseases,asthma is an immune-mediated inflammatory disease with complex triggering mechanisms and strong heterogeneity.With the in-depth study of physiological and pathological mech-anisms,therapeutic small molecule and hormone drugs have been introduced to control and treat most patients,but about 5％-10％of patients still suffer from various subtypes of difficult to control and treat asthma,that is,severe asthma.In the past decade,with the rapid development of bio-pharmaceutical research,protein and antibody have become the key drugs for the treatment of se-vere asthma with high efficacy,high specificity and high safety.However,biological drugs are usually administered by injection,they cannot be noninva-sive and directly delivered into the lung to quickly absorb and take effect.Therefore,there is an ur-gent need for the introduction of inhaled biologics with quick effectiveness,convenience,economy and safety in clinical.The review summarizes the existing small molecule,hormone and biological therapy drugs,and summarizes the development of inhalable biological agents of asthma,and ana-lyzes the future prospects of the inhalable biologi-cal drugs,which is designed to deepen the percep-tion of the direction of the inhalable biological drugs research,and update the information of the field,in order to provide reference for the develop-ment of more inhalable biologics.
